Discover Opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Jul 28, 2025 to Jul 28, 2025
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Defense Threat Reduction Agency (DTRA) | Chickasaw Nation | Jul 28, 2025 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION OR NUCLEAR INJURY"
Effective Date
Sep 20, 2024
Expires
Effective: Sep 20, 2024
SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION OR NUCLEAR INJURY"
ActiveADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
Effective Date
Sep 30, 2024
Expires
Effective: Sep 30, 2024
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis